CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Rhea-AI Summary

Cumberland Pharmaceuticals (Nasdaq: CPIX) will release its third quarter 2025 financial results and provide a company update after market close on Tuesday, Nov. 4, 2025. A conference call to discuss results is scheduled for Nov. 4 at 4:30 p.m. ET. Participants must register online to receive dial‑in/PIN details or use a "Call Me" option. A replay will be available for one year via the company's Investor Relations page or the provided media-server link.

The company is a specialty pharmaceutical firm with FDA‑approved hospital and oncology products including Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ, and is running Phase II trials of ifetroban in systemic sclerosis, DMD cardiomyopathy, and idiopathic pulmonary fibrosis. For full prescribing information and product links visit the company website.

NASHVILLE, Tenn., Oct. 28, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2025 financial results and provide a Company update after the market closes on Tuesday, Nov. 4, 2025.

A conference call will be held on Nov. 4 at 4:30 p.m. Eastern Time to discuss the results and update.

The link to register is: https://register-conf.media-server.com/register/BI93f30c40680943ef8d49bc77222ec17f.

Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

A replay of the call will be available for one year and can be accessed via the Investor Relations page of Cumberland's website or by visiting https://edge.media-server.com/mmc/p/irx2ggkf.

Cumberland Pharmaceuticals is a specialty pharmaceutical company dedicated to providing unique products that improve patient care. The Company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.

The company's portfolio of FDA-approved brands includes:

• Acetadote^® (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
• Caldolor^® (ibuprofen) injection, for the treatment of pain and fever;
• Kristalose^® (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
• Sancuso^® (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
• Vaprisol^® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
• Vibativ^® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.

The Company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis, the cardiomyopathy associated with Duchenne Muscular Dystrophy and Idiopathic Pulmonary Fibrosis.

For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, found on the company's website at www.cumberlandpharma.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-q3-2025-financial-results--company-update-302597189.html

SOURCE Cumberland Pharmaceuticals Inc.

FAQ

When will Cumberland Pharmaceuticals (CPIX) announce Q3 2025 results?

The company will release Q3 2025 results after market close on Nov. 4, 2025.

What time is the Cumberland (CPIX) Q3 2025 earnings call on Nov. 4, 2025?

The conference call is scheduled for Nov. 4, 2025 at 4:30 p.m. ET.

How do investors register for the Cumberland (CPIX) Nov. 4, 2025 call?

Investors must register via the provided registration link to receive dial‑in/PIN details or use the "Call Me" option.

Will there be a replay of the Cumberland (CPIX) Q3 2025 call and for how long?

Yes. A replay will be available for one year on the company's Investor Relations page or via the media‑server replay link.

Which FDA‑approved products does Cumberland (CPIX) list in its Oct. 28, 2025 release?

The release lists Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ among its approved brands.

What clinical programs did Cumberland (CPIX) mention in the Oct. 28, 2025 announcement?

Cumberland noted Phase II programs of ifetroban in systemic sclerosis, Duchenne cardiomyopathy, and idiopathic pulmonary fibrosis.